Palabras clave
Biomarcadores
Leucemia-linfoma de células T del adulto
Mielopatía asociada a HTLV-I
Cómo citar
Copyright © | Todos los derechos reservados.
La revista posee los derechos de autor exclusivos para la publicación de este artículo en los términos de la ley brasileña 9610/98.
Reproducción parcial
El uso de partes de los textos, figuras y cuestionario del artículo es libre, siendo obligatoria la citación de los autores y revista.
Reproducción total
Está expresamente prohibido y debe ser autorizado por la revista.
Resumen
Objetivo: Describir potenciales biomarcadores de HTLV-1 para el diagnóstico de enfermedades asociadas como ATL y HAM-TSP. Métodos: La búsqueda se realizó en PubMed Central con artículos en inglés desde junio de 2017 hasta junio de 2023, con los descriptores "HTLV-1", "Biomarkers" y "Neuroinflammatory Diseases". Tras cribar títulos y resúmenes, se seleccionaron artículos experimentales en inglés que abordaran el HTLV-1 y los biomarcadores diagnósticos de laboratorio. Se excluyeron los informes de casos, las revisiones, los comentarios, las cartas al editor y los artículos fuera del ámbito. Los artículos elegibles fueron leídos en su totalidad. Resultados: Inicialmente se encontraron 133 artículos, pero sólo 23 cumplían los criterios de inclusión. Los principales hallazgos incluyeron biomarcadores prometedores para el diagnóstico de ATL y HAM-TSP, como CXCL10, neopterina, CHIT1, ANXA1 y polimorfismos genéticos del receptor de neurotrofina p75. Consideraciones finales: Esta investigación identificó biomarcadores prometedores en la infección por HTLV-1 y HAM/TSP, tales como CXCL10, neopterina, CHIT1, ANXA1 y polimorfismos genéticos del receptor de neurotrofina p75. Sin embargo, se necesitan más estudios con muestras más grandes para validar su utilidad clínica en el diagnóstico y tratamiento de estas afecciones.
Referencias
ASSONE T, et al. Systemic cytokines and GlycA discriminate disease status and predict corticosteroid response in HTLV-1-associated neuroinflammation. Journal of neuroinflammation, 2022; 19(1): 293.
BENENCIO P, et al. HLA-B*35 as a new marker for susceptibility to human T-cell lymphotropic virus type 1 (HTLV-1) Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) in patients living in Argentina. Retrovirology, 2020; 17(1): 29.
CAMPOS KR. Estratégias de melhoria, expansão do diagnóstico e monitoramento das infecções por HTLV-1 e HTLV-2 nas coinfecções por HIV, HBV e HCV. Tese (Doutorado em Ciências) – Secretaria de Estado da Saúde de São Paulo, Programa de Pós-Graduação em Ciências da Coordenadoria de Controle de Doenças, São Paulo, 2020.
CAPORALI JFM, et al. Intrarater and interrater agreement and reliability of vestibular evoked myogenic potential triggered by galvanic vestibular stimulation (galvanic-VEMP) for HTLV-1 associated myelopathy testing. PloS one, 2018; 13(9): e0204449.
DE ASSIS IM, et al. Análise dos níveis de carga proviral em portadores de HTLV-1 com diferentes condições de comprometimento neurológico. Research, Society and Development, 2021; 12(3): e22310313264-e22310313264.
DE SOUZA MC e GAGLIANI LH. HTLV–vírus linfotrópico humano: aspectos clínicos, epidemiológico, diagnóstico e controle da doença. UNILUS Ensino e Pesquisa, 2021; 17(49): 132-155.
ENOSE-AKAHATA Y e JACOBSON S. Immunovirological markers in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology, 2019; 16: 1-14.
FLISTER GVS, et al. Prevalência de casos de HTLV entre doadores de sangue no Brasil: uma revisão integrativa. Brazilian Journal of Health Review, 2023; 6(3): 11999-12010.
FREITAS NL, et al. Lessons from the Cerebrospinal Fluid Analysis of HTLV-1-Infected Individuals: Biomarkers of Inflammation for HAM/TSP Development. Viruses, 2022; 14(10): 2146.
GHOBADI MZ, et al. Decoding pathogenesis factors involved in the progression of ATLL or HAM/TSP after infection by HTLV-1 through a systems virology study. Virology journal, 2021; 18(1): 175.
GOMES YCP, et al. Chitotriosidase 1 in the cerebrospinal fluid as a putative biomarker for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) progression. Frontiers in immunology, 2022; 13: 949516.
IBAÑEZ VR, et al. Basic zipper protein (HBZ): biomarcador diagnóstico y de seguimiento de leucemia/linfoma T del adulto. Revista Cubana de Hematología, Inmunología y Hemoterapia, 2023; 39(1).
LEAL FE, et al. Comprehensive Antiretroviral Restriction Factor Profiling Reveals the Evolutionary Imprint of the ex Vivo and in Vivo IFN-β Response in HTLV-1-Associated Neuroinflammation. Frontiers in microbiology, 2018; 9: 985.
LIMA JE, et al. Protein Profile of Blood Monocytes is Altered in HTLV-1 Infected Patients: Implications for HAM/TSP Disease. Scientific reports, 2018; 8(1): 14354.
MOHANTY S e HARHAJ EW. Mechanisms of oncogenesis by HTLV-1 Tax. Pathogens, 2020; 9(7): 543.
NAITO T, et al. Distinct gene expression signatures induced by viral transactivators of different HTLV-1 subgroups that confer a different risk of HAM/TSP. Retrovirology, 2018; 15(1): 72.
NECO HVPC, et al. Mediators Go Together: High Production of CXCL9, CXCL10, IFN-γ, and TNF-α in HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. AIDS research and human retroviruses, 2017; 33(11): 1134-1139.
PEREIRA WA e MESQUITA EM. Vírus linfotrópico de células t humana (HTLV): doenças associadas e dificuldades no diagnóstico e tratamento. Rev. Ciênc. Saúde, 2015; 17(1): 40-46.
POIESZ BJ, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. U.S.A. 1980; 77: 7415-7419.
QUEIROZ GAN, et al. Functional capacity of natural killer cells in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients. BMC infectious diseases,2019; 19(1): 433.
QUEIROZ MAF, et al. Association of the p75NTR Ser205Leu Polymorphism with Asymptomatic HTLV-1 Infection. Viruses, 2022; 14(6): 1175.
ROCAMONDE B, et al. Immunoprofiling of fresh HAM/TSP blood samples shows altered innate cell responsiveness. PLoS neglected tropical diseases, 2021; 15(11): e0009940.
ROSA DV, et al. Plasma and cerebrospinal fluid levels of cytokines as disease markers of neurologic manifestation in long-term HTLV-1 infected individuals. Biomarkers in medicine, 2018; 12(5): 447-454.
ROSADAS C, et al. Protocolo Brasileiro para Infecções Sexualmente Transmissíveis 2020: infecção pelo vírus linfotrópico de células T humanas (HTLV). Epidemiologia e Serviços de Saúde, 2021; 30(1): e2020605.
ROSADAS, C. et al. Neurofilament light in CSF and plasma is a marker of neuronal damage in HTLV-1–associated myelopathy and correlates with neuroinflammation. Neurology(R) neuroimmunology & neuroinflammation, 2021, 8(6): e1090.
SAEIDI M, et al. XCL1, a serum biomarker in neurological diseases; HTLV-1-associated myelopathy and multiple sclerosis. Microbial pathogenesis, 2023; 174: 105962.
SAFFARI M, et al. Coevolution of HTLV-1-HBZ, Tax, and proviral load with host IRF-1 and CCNA-2 in HAM/TSP patients. Infection, genetics and evolution: journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2022; 103: 105337.
SANTANA BB, et al. Low Annexin A1 level in HTLV-1 infected patients is a potential biomarker for the clinical progression and diagnosis of HAM/TSP. BMC infectious diseases, 2021; 21(1): 219.
SANTOS GPM. Estudo de possíveis biomarcadores inflamatórios no plasma de indivíduos vivendo com HTLV-1. Trabalho de conclusão de curso - (Graduação) Universidade Federal do Rio de Janeiro, Instituto de Microbiologia, Bacharel em Ciências Biológicas: Microbiologia e Imunologia, Rio de Janeiro, 2022.
SANTOS JLA. Infecção pelo HTLV-1 e progressão para HAM/TSP: contribuição de marcadores moleculares humanos e virais. Tese (Doutorado em Bioquímica e Biologia Molecular) - Universidade Federal da Bahia, Instituto de Ciências da Saúde – ICS, Programa de Pós-Graduação Multicêntrico em Bioquímica e Biologia Molecular, Salvador, 2021.
SANTOS TM. Identificação de biomarcadores transcricionais associados às principais manifestações clínicas da infecção pelo HTLV-1. Tese – (Mestrado em Bioquímica e Biologia Molecular), Universidade Federal da Bahia, Instituto de Ciências da Saúde, Programa de Pós-Graduação Multicêntrico em Bioquímica e Biologia Molecular, Salvador, 2020.
SATO T, et al. Proposal of Classification Criteria for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Disease Activity. Frontiers in microbiology, 2018; 9: 1651.
SCHIERHOUT G, et al. Association between HTLV-1 infection and adverse health outcomes: a systematic review and meta-analysis of epidemiological studies. The Lancet Infectious Diseases, 2020; 20(1): 133-143.
SCHOR D, et al. Lack of association between single-nucleotide polymorphisms of pro- and anti-inflammatory cytokines and HTLV-1-associated myelopathy/tropical spastic paraparesis development in patients from Rio de Janeiro, Brazil. BMC infectious diseases, 2018; 18(1): 593.
SCHRIEFER A e CARVALHO EM. Biomarcadores em medicina. Gazeta Médica da Bahia, 2008; 78(1): 47-51.
SOUZA FDS, et al. Following the Clues: Usefulness of Biomarkers of Neuroinflammation and Neurodegeneration in the Investigation of HTLV-1-Associated Myelopathy Progression. Frontiers in immunology, 2021; 12: 737941.
TAKENOUCHI N, et al. Expression of TSLC1 in patients with HAM/TSP. Journal of neurovirology, 2023; 26(3): 404-414.
TAMAKI K, et al. Cerebrospinal Fluid CXCL10 as a Candidate Surrogate Marker for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. Frontiers in microbiology,2019; 10: 2110.
TOVAR LLANOS V, et al. Mielopatía asociada con infección por HTLV-1: paraparesia espástica tropical. Acta Neurológica Colombiana, 2021; 37(1): 40-46.